Human medicines European public assessment report (EPAR): Edistride, dapagliflozin, Date of authorisation: 09/11/2015, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Date of authorisation: 11/11/2012, Revision: 34, Status: Authorised

Change management activities delivery plan - HMA-EMA joint Big Data Steering Group

Human medicines European public assessment report (EPAR): Byannli (previously Paliperidone Janssen-Cilag International), paliperidone, Date of authorisation: 18/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Date of authorisation: 20/09/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 10, Status: Authorised